| # | Drug | Count |
|---|---|---|
| 0 | LORATADINE | 3 |
| 1 | LORATADINE ORAL | 3 |
| 2 | NALTREXONE | 3 |
| 3 | PHENYTOIN | 3 |
| 4 | ACETAMINOPHEN | 2 |
| 5 | ACETAMINOPHEN 500MG | 2 |
| 6 | ACETAMINOPHEN TABLET EXTENDED RELEASE | 2 |
| 7 | CYCLOPHOSPHAMIDE | 2 |
| 8 | CYCLOPHOSPHAMIDE FOR INJECTION | 2 |
| 9 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 2 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ETOPOSIDE PHOSPHATE | 1 | 0.0006 |
| 1 | MIFEPRISTONE | 1 | 0.0002 |
| 2 | ZONISAMIDE | 2 | 0.0002 |
| 3 | BISMUTH SUBSALICYLATE | 1 | 0.0002 |
| 4 | PRAZOSIN | 1 | 0.0002 |
| 5 | PHENYTOIN | 3 | 0.0001 |
| 6 | NALTREXONE | 3 | 0.0001 |
| 7 | STANDARDIZED SENNA CONCENTRATE | 1 | 0.0001 |
| 8 | CRIZOTINIB | 1 | 0.0001 |
| 9 | ROMIPLOSTIM | 1 | 0.0001 |
| # | Drug class | Count |
|---|---|---|
| 0 | Anti-epileptic Agent [EPC] | 3 |
| 1 | Alkylating Drug [EPC] | 2 |
| 2 | Expectorant [EPC] | 2 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 2 |
| 4 | Aluminum Complex [EPC] | 1 |
| 5 | Aromatase Inhibitor [EPC] | 1 |
| 6 | Bismuth [EPC] | 1 |
| 7 | CD20-directed Cytolytic Antibody [EPC] | 1 |
| 8 | Central alpha-2 Adrenergic Agonist [EPC] | 1 |
| 9 | Corticosteroid [EPC] | 1 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Progestin Antagonist [EPC] | 1 | 0.0002 |
| 1 | Bismuth [EPC] | 1 | 0.0002 |
| 2 | Sigma-1 Agonist [EPC] | 1 | 0.0001 |
| 3 | Thrombopoietin Receptor Agonist [EPC] | 1 | 0.0001 |
| 4 | Human Immunoglobulin G [EPC] | 1 | 0.0000 |
| 5 | Aluminum Complex [EPC] | 1 | 0.0000 |
| 6 | Pyrimidine Synthesis Inhibitor [EPC] | 1 | 0.0000 |
| 7 | Central alpha-2 Adrenergic Agonist [EPC] | 1 | 0.0000 |
| 8 | Anti-epileptic Agent [EPC] | 3 | 0.0000 |
| 9 | Expectorant [EPC] | 2 | 0.0000 |